Dr Sophia Malandraki-Miller's research combines the fields of Stem Cell Therapy, Drug Discovery, Metabolism, and Cardiac Sciences. Sophia studied Applied Biology & Biotechnology in Greece. She then completed her PhD studies at the Department of Physiology, Anatomy & Genetics, of University of Oxford, focusing on progenitor cell differentiation, metabolism, and miRNAs. Upon completion of her DPhil, in 2017 she was offered a Postdoctoral position, in Professor Paul Riley's group and OxStem Cardio, which allows her to approach stem cell therapy from the promising angle of phenotypic drug discovery. Currently, Sophia works on the identification of small molecules that can stimulate the endogenous progenitor cells, in the adult human heart, to contribute in muscle regeneration after myocardial infarction.
Dr Sophia Malandraki-Miller has a strong interest in research translation, and entrepreneurship. Through her work she aims to contribute to the development of regenerative therapies for patients with ischaemic heart disease, and to discover the first drug for myocardial infarction treatment.